Discover 1,527 paid clinical trials in Boulder, Colorado. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,527
Project Dulce for Arab Americans With Type 2 Diabetes
for
Diabetes Mellitus, Type 2
Location: Denver CO
Sponsor: Scripps Whittier Diabetes Institute
Sex: All
Age: 18+
Code: NCT05580536
Recruiting
The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population
for
Kidney Injury
Location: Denver CO, Boston MA
Sponsor: BioPorto Diagnostics
Sex: All
Age: 18+
Code: NCT03057457
Recruiting
Non-invasive Test to Detect Intra-amniotic Infection in Women With Preterm Labor and Intact Amniotic Membranes
for
Intra-amniotic Infection
Location: Denver CO, Mesa AZ, Phoenix AZ, Tucson AZ, St. Louis MO,
Sponsor: ProteoGenix, Inc.
Sex: Female
Age: 18+
Code: NCT00700219
Recruiting
A Study of PYX-201 in Advanced Solid Tumors
for
Solid Tumor, Advanced Solid Tumor
Location: Denver CO, Scottsdale AZ, Dallas TX, St Louis MO,
Sponsor: Pyxis Oncology, Inc
Sex: All
Age: 18+
Code: NCT05720117
Phase1, Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Location: Denver CO, Salt Lake City UT, Dallas TX, Austin TX,
Sponsor: NiKang Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06586957
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
for
Adult Spinal Deformity, Scoliosis, Kyphosis
Location: Denver CO, Phoenix AZ, Shreveport LA, La Jolla CA,
Sponsor: International Spine Study Group Foundation
Sex: All
Age: 18+
Code: NCT04888104
Recruiting
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
for
Solid Tumors, Adult
Location: Denver CO, Cleveland OH, Plantation FL
Sponsor: Hutchmed
Sex: All
Age: 18+
Code: NCT07228247
Phase1, Phase2, Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Location: Denver CO, Nashville TN, Fairfax VA, Trumbull CT,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07519655
Phase1, Recruiting
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
for
HER2 Expressing Solid Tumors
Location: Denver CO, Rochester MN, Los Angeles CA, Houston TX,
Sponsor: Vironexis Biotherapeutics Inc.
Sex: All
Age: 18+
Code: NCT07192432
Phase1, Phase2, Recruiting
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Location: Denver CO, Dallas TX, Houston TX, Chicago IL, Eugene OR,
Sponsor: Institut de Recherches Internationales Servier
Sex: All
Age: 18+
Code: NCT06465953
Phase3, Recruiting
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
for
MTAP-deleted Solid Tumors
Location: Denver CO, Irving TX, San Antonio TX, Milwaukee WI,
Sponsor: Bayer
Sex: All
Age: 18+
Code: NCT06914128
Phase1, Phase2, Recruiting
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
for
Infusion Reactions
Location: Denver CO, Aurora CO, Omaha NE, Oklahoma City OK,
Sponsor: New York Blood Center
Sex: All
Age: 0+
Code: NCT01656603
Phase2, Recruiting
New
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
for
Multiple Myeloma
Location: Denver CO
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT04910568
Phase1, Recruiting
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
for
Chronic Lymphocytic Leukemia (CLL),
Location: Denver CO, Salt Lake City UT, Duarte CA, Houston TX,
Sponsor: Nurix Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT04830137
Phase1, Recruiting
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML